1 May 2026
The Medannex team are grateful to the Cholangiocarcinoma Foundation for inviting us to participate in their very insightful Annual Conference in Salt Lake City, Utah. It was a valuable opportunity to learn about the latest advancements in the field and to share our promising clinical data in this area of significant unmet medical need.
We are encouraged by the results observed so far, including evidence of tumour shrinkage alongside a strong safety profile. Our sincere thanks go to all participants involved in the first-in-human study of MDX-124.
Our poster presentation can be viewed here: Medannex.org/CCF-Poster
We look forward to sharing further data as the tumour-specific phase of the ATTAINMENT study progresses.